ProKidney Corp. (PROK)Healthcare | Biotechnology | Winston-Salem, United States | NasdaqCM
1.33 USD
-0.13
(-8.715%) ⇩
(Oct. 16, 2026, 2:10 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:47 a.m. EDT
ProKidney is a classic high-risk biotech play defined by extreme volatility and a lack of financial stability. The company is burning cash aggressively, with operating cash flow in the negative $140 million range and negative revenue growth of 32%, while trading at a price-to-sales ratio of nearly 850x. Fundamentally, the business is deteriorating; despite a recent year-over-year price recovery, the underlying metrics show a multi-year decline in value, making it a poor candidate for long-term holding. The stock is essentially a speculative vehicle for a single successful clinical trial or partnership deal. Short-term, the technicals are mixed but leaning slightly negative due to the heavy selling pressure and the fact that the price is still trading below its 200-day moving average. The statistical forecast offers no directional edge, which aligns with the chaotic nature of the asset. While the options market is screaming for a big move—likely driven by the hope of a binary event—the probability of success is obscured by the company's precarious financial state. Investors here are not buying a company; they are buying a lottery ticket with a very high premium. Given the lack of dividends, the burning cash pile, and the weak statistical outlook, the risk-reward profile is unfavorable for most investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.178313 |
| AutoTheta | 0.184458 |
| AutoETS | 0.184888 |
| AutoARIMA | 0.184892 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 0.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.305 |
| Excess Kurtosis | -0.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.581 |
| Revenue per Share | 0.005 |
| Market Cap | 530,314,048 |
| Forward P/E | -2.27 |
| Beta | 1.80 |
| Website | https://prokidney.com |
As of Oct. 10, 2026, 6:47 a.m. EDT: Speculators are heavily positioned for upside volatility with massive open interest in out-of-the-money calls (strikes $3.00-$4.00) across multiple expirations, suggesting a belief in a potential biotech catalyst or binary event. However, there is a significant and growing defensive put wall at the $2.00-$3.00 strikes, particularly in January 2027, indicating a 'long gamma' setup where traders are betting on a sharp move in either direction rather than a steady grind higher.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.510101 |
| Address1 | 2,000 Frontis Plaza Boulevard |
| Address2 | Suite 250 |
| All Time High | 14.19 |
| All Time Low | 0.46 |
| Ask | 1.68 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,162,730 |
| Average Daily Volume3 Month | 1,297,275 |
| Average Volume | 1,297,275 |
| Average Volume10Days | 1,162,730 |
| Beta | 1.796 |
| Bid | 1.05 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | -4.295 |
| City | Winston-Salem |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.3285 |
| Current Ratio | 8.356 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.4744 |
| Day Low | 1.305 |
| Debt To Equity | 1.581 |
| Display Name | ProKidney |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -170,370,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.233 |
| Enterprise To Revenue | 1,506.501 |
| Enterprise Value | 1,232,317,696 |
| Eps Current Year | -0.5622 |
| Eps Forward | -0.58647 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6833 |
| Fifty Day Average Change | -0.3548 |
| Fifty Day Average Change Percent | -0.21077643 |
| Fifty Two Week Change Percent | -51.0101 |
| Fifty Two Week High | 3.48 |
| Fifty Two Week High Change | -2.1515 |
| Fifty Two Week High Change Percent | -0.6182471 |
| Fifty Two Week Low | 1.3 |
| Fifty Two Week Low Change | 0.02850008 |
| Fifty Two Week Low Change Percent | 0.02192314 |
| Fifty Two Week Range | 1.3 - 3.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,059,800,000 |
| Float Shares | 184,645,452 |
| Forward Eps | -0.58647 |
| Forward P E | -2.265248 |
| Free Cashflow | -83,844,872 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 231 |
| Fullday Change | -0.12650001 |
| Fullday Change Percent | -8.715123 |
| Fullday Price | 1.3285 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 818,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.46453997 |
| Held Percent Institutions | 0.26534998 |
| Implied Shares Outstanding | 399,182,568 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. |
| Long Name | ProKidney Corp. |
| Market | us_market |
| Market Cap | 530,314,048 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_598380790 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -84,159,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 382,336,302 |
| Number Of Analyst Opinions | 6 |
| Open | 1.43 |
| Operating Cashflow | -141,167,008 |
| Operating Margins | -322.4867 |
| Overall Risk | 7 |
| Phone | 336 999 7019 |
| Previous Close | 1.455 |
| Price Eps Current Year | -2.363038 |
| Price Hint | 4 |
| Price To Book | -0.30931315 |
| Price To Sales Trailing12 Months | 648.30566 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.037 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.12650001 |
| Regular Market Change Percent | -8.715123 |
| Regular Market Day High | 1.4744 |
| Regular Market Day Low | 1.305 |
| Regular Market Day Range | 1.305 - 1.4744 |
| Regular Market Open | 1.43 |
| Regular Market Previous Close | 1.455 |
| Regular Market Price | 1.3285 |
| Regular Market Time | 1,792,174,230 |
| Regular Market Volume | 1,414,326 |
| Return On Assets | -0.35662997 |
| Return On Equity | -0.58956003 |
| Revenue Growth | -0.321 |
| Revenue Per Share | 0.005 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 208,926,941 |
| Shares Percent Shares Out | 0.113800004 |
| Shares Short | 23,785,320 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 20,737,263 |
| Short Name | ProKidney Corp. |
| Short Percent Of Float | 0.1531 |
| Short Ratio | 14.27 |
| Source Interval | 15 |
| State | NC |
| Symbol | PROK |
| Target High Price | 12.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 6.25 |
| Target Median Price | 5.75 |
| Total Cash | 181,564,000 |
| Total Cash Per Share | 0.869 |
| Total Debt | 3,523,000 |
| Total Revenue | 818,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.86525 |
| Two Hundred Day Average Change | -0.53674996 |
| Two Hundred Day Average Change Percent | -0.287763 |
| Type Disp | Equity |
| Volume | 1,414,326 |
| Website | https://prokidney.com |
| Zip | 27,103 |